NCT03319901 - Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 30, 2017

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2027

Conditions

Leukemia

Interventions

DRUG

Venetoclax

"Venetoclax is an inhibitor of Bcl-2. Bcl-2 is critical for keeping cancer cells alive.~By inhibiting Bcl-2, venetoclax promotes cancer cell death."

DRUG

Standard Chemotherapy

Standard treatment of chemotherapy is administered

Trial Locations (5)

RECRUITING

University of Chicago, Chicago

RECRUITING

MD Anderson Cancer Center, Houston

RECRUITING

Intermountain LDS Hospital, Salt Lake City

RECRUITING

Massachusetts General Hospital, Boston

RECRUITING

Dana Farber Cancer Institute, Boston